The newest verified discoveries, filterable by cancer type, evidence stage, advance type, intervention type, and biomarker — sorted by publish date, review date, or update date. Only Verified, non-suppressed stories appear here.
In the randomized, double-blind, placebo-controlled INAVO120 trial, adding inavolisib to palbociclib and fulvestrant significantly delayed disease progression compared with palbociclib and fulvestrant alone, in a PIK3CA-mutated, endocrine-resistant, first-line metastatic breast…
In the randomized, double-blind, placebo-controlled INDIGO trial, vorasidenib significantly delayed disease progression (by blinded independent review) and delayed the time to the next anticancer intervention, compared with placebo, in a…
Afamitresgene autoleucel is an engineered T-cell therapy — reportedly the first engineered cell therapy approved for a solid tumor in the United States — that received accelerated approval based on…